Skip to main content
. 2018 Jul 23;8:11069. doi: 10.1038/s41598-018-29332-7

Table 2.

Mucinous carcinoma samples overview.

Sample Status Metastasis Treatment Stage Grade Diagnosis Specific immunostaining
1 alive without disease none carboplatin/paclitaxel IC BOT Endometrioid adenocarcinoma with focal mucinous differentiation mCEA+/− (extracellular), ER+, PAX8+
2 dead, unknown reason NA carboplatin/paclitaxel NA 1 Mucinous adenocarcinoma CK7+, CK20+/−, PAX8+
3 alive without disease none none IA BOT Mucinous cystadenoma mCEA+, CK7+, CK20+, PAX8+
4 dead of disease recurrence oxaliplatin and Xeloda, 5FU IIIB 1 Mucinous adenocarcinoma CK7+, CK20−, PAX8+
5 dead of disease pelvic tumor carboplatin/paclitaxel IIIC NA Mucinous adenocarcinoma of uncertain origin in the ovary mCEA+, CK7 focally+, CK20 focally+, PAX8−
6 dead of disease pelvic tumor carboplatin/paclitaxel IIIC NA Mucinous adenocarcinoma of uncertain origin in the ovary PAX8−
7 dead of disease recurrence palliative NA NA Low-grade mucinous carcinoma Archival slides unavailable for reassessment
8 dead of disease pelvic tumor, liver none IA BOT Mucinous carcinomas CK7+, CK20−, PAX8+
9 dead of other reason none none IC 2 Mucinous adenocarcinoma with neuroendocrine differentiation mCEA+/−, CK7+, CK20−, PAX8+, Synaptophysin+/−, Chromogranin A+/−
10 dead of disease, after recurrence residual tumor none IIIC 2 Mucinous adenocarcinoma of uncertain origin in the ovary mCEA+, CK7+, CK20+, CDX2+/−, PAX8−
11 alive without disease none none IA 1 Mucinous adenocarcinoma mCEA+, CK7+, CK20+/−, PAX8−, CDX2−, ER−, PR−
12 alive without desease none none IIC 1 Mucinous adenocarcinoma mCEA+/−, CK7+, CK20+/−, PAX8+, CDX2+/−, CA 125−
13 Alive without disease rectum Adjuvant Oxaliplatin and Xeloda IIB NA Mucinous adenocarcinoma CEA+, CK7+, CK20+, CDX2+/−
14 Alive without disease none none IA 1 Mucinous adenocarcinoma CEA+, CK7+, CK20−, CDX2−
15 Alive without disease none none IA NA Mucinous adenocarcinoma Archival slides unavailable for reassessment
16 Alive with disease pelvic tumor HIPEC with MitomycinC IVb 2 with neuroendocrine differentiation Mucinous adenocarcinoma CEA+, CK7+, CK20+, CDX2+, Vilin
17 Dead of disease pelvic tumor none IA 1 Mucinous adenocarcinoma Archival slides unavailable for reassessment
18 Alive without disease pelvic tumor none IA 1 Mucinous adenocarcinoma Archival slides unavailable for reassessment
19 Alive without disease pelvic tumor none IC 1 Mucinous adenocarcinoma CK7+, CK20+, CDX2+, PAX8+